Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
Ramalingam, S Crawford, J Chang, A Manegold, C Perez-Soler, R Douillard, J-Y Thatcher, Nick Barlesi, F Owonikoko, T Wang, Y
Ramalingam, S
Crawford, J
Chang, A
Manegold, C
Perez-Soler, R
Douillard, J-Y
Thatcher, Nick
Barlesi, F
Owonikoko, T
Wang, Y
Citations
Altmetric:
Abstract
Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced non-small-cell lung cancer (NSCLC).
Affiliation
Description
Date
2013-11
Publisher
Collections
Keywords
Type
Article
Citation
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). 2013, 24 (11):2875-80 Ann Oncol